Stockreport

Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer

Turning Point Therapeutics, Inc. - Common stock  (TPTX) 
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am Check Earnings Report
PDF SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that t [Read more]